Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.
Antimicrob Agents Chemother
; 53(5): 2185-8, 2009 May.
Article
em En
| MEDLINE
| ID: mdl-19223634
ABSTRACT
In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by complete gag genotypic and phenotypic testing of 20 patient-derived human immunodeficiency virus type 1 isolates and 20 site-directed mutants. We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
Succinatos
/
Triterpenos
/
HIV-1
/
Inibidores da Protease de HIV
/
Fármacos Anti-HIV
/
Produtos do Gene gag do Vírus da Imunodeficiência Humana
Limite:
Humans
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article